Breaking Finance News

ValuEngine upgraded Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to Sell in a report released today.

ValuEngine has upgraded Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to Sell in a report released on Tuesday June 20, 2017.

Previously on Tuesday May 16, 2017, Needham reported about Alder Biopharmaceuticals Inc (NASDAQ:ALDR) raised the target price from $0.00 to $36.00. At the time, this indicated a possible upside of 1.02%.

Yesterday Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded 2.51% higher at $19.10. The company’s 50-day moving average is $9.66 and its 200-day moving average is $16.05. The last stock close price is up -36.44% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 6,546,066 shares of the stock were exchanged, up from an average trading volume of 1,983,950

See Chart Below

Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder Biopharmaceuticals Inc has a 52 week low of $8.60 and a 52 week high of $35.62 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $47.00 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.